Home › Compare › IGNT vs MRK

IGNT vs MRK: Dividend Comparison 2026

IGNT yields 10000000.00% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IGNT wins by $4.762052817831319e+46M in total portfolio value
10 years
IGNT
IGNT
● Live price
10000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.762052817831319e+46M
Annual income
$47,619,591,428,874,056,000,000,000,000,000,000,000,000,000,000,000,000.00
Full IGNT calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — IGNT vs MRK

📍 IGNT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIGNTMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IGNT + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IGNT pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IGNT
Annual income on $10K today (after 15% tax)
$850,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$40,476,652,714,542,950,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, IGNT beats the other by $40,476,652,714,542,950,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IGNT + MRK for your $10,000?

IGNT: 50%MRK: 50%
100% MRK50/50100% IGNT
Portfolio after 10yr
$2.3810264089156593e+46M
Annual income
$23,809,795,714,437,028,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

IGNT
No analyst data
Altman Z
-75.7
Piotroski
4/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IGNT buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIGNTMRK
Forward yield10000000.00% ✓2.81%
Annual dividend / share$2.00$3.32 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7% ✓
Portfolio after 10y$4.762052817831319e+46M$57.7K ✓
Annual income after 10y$47,619,591,428,874,056,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓$10,113.78
Total dividends collected$4.762046689458665e+46M$29.8K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IGNT vs MRK ($10,000, DRIP)

YearIGNT PortfolioIGNT Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$1,000,010,700$1,000,000,000.00$11,213$373.04+$1000.00M → IGNT
2$93,460,013,936,683$93,458,943,925,233.62$12,667$512.06+$93460013.92M → IGNT
3$8,163,259,573,940,183,000$8,163,159,571,725,270,000.00$14,439$708.14+$8163259573940.17M → IGNT
4$666,373,880,559,373,300,000,000$666,365,145,871,629,100,000,000.00$16,640$988.16+$666373880559373312.00M → IGNT
5$50,838,057,311,279,720,000,000,000,000$50,837,344,291,227,520,000,000,000,000.00$19,432$1,394.07+$5.083805731127972e+22M → IGNT
6$3,624,737,622,195,432,400,000,000,000,000,000$3,624,683,225,474,109,500,000,000,000,000,000.00$23,057$1,992.90+$3.6247376221954326e+27M → IGNT
7$241,535,451,261,763,920,000,000,000,000,000,000,000$241,531,572,792,508,160,000,000,000,000,000,000,000.00$27,889$2,894.79+$2.4153545126176394e+32M → IGNT
8$15,041,872,435,857,020,000,000,000,000,000,000,000,000,000$15,041,613,992,924,168,000,000,000,000,000,000,000,000,000.00$34,518$4,286.29+$1.504187243585702e+37M → IGNT
9$875,466,765,540,973,800,000,000,000,000,000,000,000,000,000,000$875,450,670,737,467,500,000,000,000,000,000,000,000,000,000,000.00$43,912$6,494.35+$8.754667655409739e+41M → IGNT
10$47,620,528,178,313,184,000,000,000,000,000,000,000,000,000,000,000,000$47,619,591,428,874,056,000,000,000,000,000,000,000,000,000,000,000,000.00$57,714$10,113.78+$4.762052817831319e+46M → IGNT

IGNT vs MRK: Complete Analysis 2026

IGNT — Stock

Ingen Technologies, Inc., a medical device manufacturing company, manufactures medical products for the respiratory industry in United States. The company manufactures medical equipment for patients suffering with chronic obstructive pulmonary disease; and oxygen flow meters and nasal cannulas under the Oxyview and Smart Nasal Cannula trademark name. Its Oxyview is a pneumatic metering device that displays and confirms the oxygen flow rate near the patient. Ingen Technologies, Inc. was founded in 1999 and is based in Riverside, California.

Full IGNT Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this IGNT vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IGNT vs SCHDIGNT vs JEPIIGNT vs OIGNT vs KOIGNT vs MAINIGNT vs JNJIGNT vs ABBVIGNT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.